New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
12:31 EDTZIOP, BRK.A, RFMD, GS, CLMT, SONCOn The Fly: Midday Wrap
Stocks on Wall Street were higher right out of the gate and have not moved far from their opening levels near midday. Investors received a fair amount of domestic economic data, including better than expected reports on home prices and durable goods orders. The flip side, however, was some worse than expected consumer confidence and new home sales data. Despite the mixed data, the market seems intent on closing the quarter with its gains intact as the end of the month approaches... ECONOMIC EVENTS: In the U.S., overall orders for durable goods rose 5.7% in February, versus expectations for an increase of 3.9%. However, excluding transportation, orders slipped 0.5%, versus expectations for a 0.6% rise. The S&P/Case-Shiller 20-city home price index climbed 8.1% in the 12 months ending in January, after rising 6.8% a month earlier. New home sales dropped 4.6% to 411K in February, versus expectations for a decline to 414K. Consumer confidence fell 8.3 points to 59.7 in March, which was worse than the expected pull back to 69.0. The Richmond Fed manufacturing survey reading of 3 for March missed expectations for it to hold at 6... COMPANY NEWS: Goldman Sachs (GS) announced that it amended its warrant agreement with Berkshire Hathaway (BRK.A) to settle in terms of net shares in place of a cash settlement, quoting Berkshire's Chairman and CEO Warren Buffett as having said, "We intend to hold a significant investment in Goldman Sachs." Shares of Goldman, which rose early in the session, were down fractionally near noon... MAJOR MOVERS: Among the notable gainers were Sonic (SONC), which rose 8% following its earnings report, and RF Micro Devices (RFMD), which rallied nearly 6% after Oppenheimer upgraded the stock to an Outperform rating. Among the noteworthy losers was Ziopharm (ZIOP), which was downgraded by at least four analyst firms and plunged over 61% after terminating development of a cancer drug after a clinical study missed its goal. Also lower were shares of Calumet Specialty Products (CLMT), down 4% after an offering of 5.25M of its shares priced at $37.50... INDICES: Near midday, the Dow was up 74.84, or 0.52%, to 14,522.59; the Nasdaq was up 5.90, or 0.18%, to 3,241.20; and the S&P 500 was up 6.36, or 0.41%, to 1,558.05.
News For A;SONC;RFMD;ZIOP;CLMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
08:29 EDTCLMTCalumet Specialty Products management to meet with JPMorgan
Subscribe for More Information
January 27, 2015
11:06 EDTAAgilent announces China FDA approval of SureScan Dx microarray scanner
Subscribe for More Information
10:54 EDTZIOPZiopharm February volatility elevated at 135
Subscribe for More Information
January 20, 2015
13:21 EDTZIOPCAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
05:54 EDTZIOPStocks with implied volatility movement; ZIOP INVN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use